EP 4157284 A1 20230405 - USE OF NMN TO REDUCE IMMUNODEPRESSION AND IMMUNOSENESCENCE
Title (en)
USE OF NMN TO REDUCE IMMUNODEPRESSION AND IMMUNOSENESCENCE
Title (de)
VERWENDUNG VON NMN ZUR VERRINGERUNG VON IMMUNDEPRESSION UND IMMUNSENESZENZ
Title (fr)
UTILISATION DE NMN POUR REDUIRE L'IMMUNODEPRESSION ET L'IMMUNOSENESCENCE
Publication
Application
Priority
- FR 2005739 A 20200529
- EP 2021064121 W 20210526
Abstract (en)
[origin: WO2021239850A1] The invention relates to nicotinamide mononucleotide, one of the pharmaceutically acceptable derivatives thereof, one of the pharmaceutically acceptable precursors thereof or one of the pharmaceutically acceptable salts thereof, for use in reducing immunosenescence and/or enhancing immune response to vaccination, and further relates to compositions containing same.
IPC 8 full level
A61K 31/6615 (2006.01); A61K 9/00 (2006.01); A61K 31/706 (2006.01); A61K 39/00 (2006.01); A61P 37/02 (2006.01); A61P 37/04 (2006.01)
CPC (source: EP US)
A61K 31/6615 (2013.01 - EP US); A61K 31/706 (2013.01 - EP US); A61K 39/39 (2013.01 - EP); A61P 37/02 (2018.01 - EP); A61P 37/04 (2018.01 - EP); A61K 2039/55561 (2013.01 - EP)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
FR 3110836 A1 20211203; FR 3110836 B1 20230616; CN 115968294 A 20230414; EP 4157284 A1 20230405; US 2023136569 A1 20230504; WO 2021239850 A1 20211202
DOCDB simple family (application)
FR 2005739 A 20200529; CN 202180041663 A 20210526; EP 2021064121 W 20210526; EP 21728902 A 20210526; US 202117927478 A 20210526